Statements (31)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
beta blocker |
| gptkbp:ATCCode |
gptkb:C07AB03
|
| gptkbp:bioavailability |
50%
|
| gptkbp:brand |
gptkb:Tenormin
|
| gptkbp:CASNumber |
gptkb:29122-68-7
|
| gptkbp:contraindication |
asthma
severe bradycardia cardiogenic shock |
| gptkbp:discoveredBy |
gptkb:ICI_Pharmaceuticals
|
| gptkbp:eliminationHalfLife |
6-7 hours
|
| gptkbp:excretion |
renal
|
| gptkbp:hasMolecularFormula |
C14H22N2O3
|
| https://www.w3.org/2000/01/rdf-schema#label |
Atenololo
|
| gptkbp:introducedIn |
1976
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
beta-1 adrenergic receptor antagonist
|
| gptkbp:metabolism |
minimal hepatic
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
oral
intravenous |
| gptkbp:sideEffect |
dizziness
fatigue bradycardia cold extremities |
| gptkbp:usedFor |
gptkb:arrhythmia
myocardial infarction hypertension angina pectoris |
| gptkbp:bfsParent |
gptkb:CHEMBL941
|
| gptkbp:bfsLayer |
7
|